On October 15, 2026, a landmark development reshaped the legal landscape for tens of millions of Americans who have taken gabapentin or pregabalin: the Philadelphia Court of Common Pleas formally established a new mass tort program consolidating dozens of cases alleging that long-term gabapentinoid use causes neurocognitive decline and early-onset dementia. The program targets Pfizer and its subsidiaries — makers of Neurontin (gabapentin) and Lyrica (pregabalin) — and represents the most significant structural litigation milestone in the gabapentin lawsuit space to date. If you or a loved one has been prescribed gabapentin long-term and later received a dementia or mild cognitive impairment (MCI) diagnosis, understanding this program and the science behind it is critical.
Breaking: Philadelphia Court Establishes Gabapentinoid Mass Tort Program (October 15, 2026)
As reported by The Legal Intelligencer on October 15, 2026, the Philadelphia Court of Common Pleas officially launched a new products-liability mass tort program specifically targeting neurocognitive harm claims tied to gabapentinoids. The program consolidates dozens of individual lawsuits in which plaintiffs allege that Pfizer failed to warn patients and physicians that prolonged gabapentin or pregabalin use is associated with measurably elevated dementia and MCI risk. This state-court consolidation in Philadelphia — one of the nation’s most experienced mass tort venues — is currently the primary litigation hub for these claims, as no nationwide federal multidistrict litigation (MDL) has been established as of late 2026.
The establishment of a dedicated mass tort program is more than a procedural milestone. It signals that Pennsylvania judges have found sufficient commonality among these claims to warrant centralized management — a critical step toward eventual discovery, bellwether trials, and the possibility of a global resolution. Plaintiffs in the gabapentin lawsuit program allege three core legal theories: failure to warn of known neurocognitive risks, off-label marketing fraud, and concealment of adverse safety data from regulators and the public. Pfizer has faced similar allegations before: in 2004, the company paid a $430 million criminal and civil settlement related to illegal off-label marketing of Neurontin, followed by additional settlements of $325 million and $190 million tied to marketing and antitrust violations — a litigation history plaintiffs argue demonstrates a pattern of prioritizing sales over patient safety.
For individuals evaluating their potential claims, using a medical malpractice calculator can provide a preliminary estimate of compensation ranges associated with defective drug injuries like those alleged in this litigation.
The Science: What Research Shows About Gabapentin and Dementia Risk
The Philadelphia mass tort program did not emerge in a vacuum. It is anchored to an accelerating body of peer-reviewed research linking long-term gabapentinoid exposure to serious neurocognitive harm — research that plaintiffs argue Pfizer had a duty to investigate, disclose, and act upon long before litigation began.
The 2025 Case Western Reserve Study
The most frequently cited evidence in gabapentin lawsuit filings is a 2025 study published in Regional Anesthesia & Pain Medicine by researchers at Case Western Reserve University. The study analyzed 26,416 adults using the TriNetX database spanning 2004 through 2024. Its findings were striking: patients who filled six or more gabapentin prescriptions faced a 29% higher 10-year dementia risk (RR 1.29; 95% CI 1.18–1.40) and an 85% higher risk of mild cognitive impairment (RR 1.85; 95% CI 1.63–2.10) compared to non-users. The risk was most pronounced among non-elderly adults ages 35–64, where risk ratios exceeded 2.0 — meaning the drug more than doubled dementia risk in working-age adults. Critically, patients filling 12 or more prescriptions faced a 40% higher dementia risk than those filling only 3 to 11 prescriptions, suggesting a dose-response relationship that strengthens the causal argument. You can review CDC guidance on long-term prescription drug risk assessment to understand how regulators evaluate chronic drug exposure data.
The June 2026 Meta-Analysis and Additional Evidence
The scientific foundation was further reinforced in June 2026, when a meta-analysis published in Drugs & Aging synthesized data from five observational studies encompassing 325,245 participants. The analysis concluded that gabapentinoid use was associated with modestly but meaningfully elevated estimated odds of Alzheimer’s disease and related dementias, and called for cautious prescribing — particularly for off-label and long-term use. Separately, a study published in Frontiers in Pharmacology found a 45% dementia risk increase among gabapentin users, while data from the National Alzheimer’s Coordinating Center database identified measurable cognitive decline in cognitively normal adults within just two years of initiating gabapentin therapy. Taken together, these findings form a scientific mosaic that plaintiffs’ attorneys argue directly supports failure-to-warn claims against Pfizer. Reviewing Cornell Law School’s overview of products liability law can help you understand the legal standards governing failure-to-warn claims in pharmaceutical litigation.
Gabapentin’s Explosive Prescription Growth and Off-Label Use Problem
Understanding the scope of potential gabapentin lawsuit liability requires grasping just how dramatically prescribing has expanded — and how much of that expansion has occurred outside the drug’s FDA-approved indications. Gabapentin received FDA approval in 1993, originally for epilepsy and postherpetic neuralgia. Over the following three decades, it became one of the most widely prescribed drugs in American medicine, dispensed for chronic back pain, anxiety, migraines, fibromyalgia, and a range of other conditions for which it carries no FDA-approved label.
| Metric | 2010 | 2024 | Source |
|---|---|---|---|
| Annual gabapentin prescriptions | 24.2 million | 58.9 million | Annals of Internal Medicine / CDC Analysis |
| Patients dispensed gabapentin annually | 5.8 million | 15.5 million | Annals of Internal Medicine / CDC Analysis |
| Dementia risk increase (6+ Rx) | — | +29% (RR 1.29) | Case Western Reserve, Regional Anesthesia & Pain Medicine, 2025 |
| MCI risk increase (6+ Rx) | — | +85% (RR 1.85) | Case Western Reserve, Regional Anesthesia & Pain Medicine, 2025 |
| Dementia risk increase (12+ Rx) | — | +40% vs. 3–11 Rx | Case Western Reserve / National Injury Advocates |
| Meta-analysis participants | — | 325,245 | Drugs & Aging, June 2026 |
| Frontiers in Pharmacology risk increase | — | +45% | Frontiers in Pharmacology |
Despite this explosion in use — and the accumulating evidence of neurocognitive risk — no dementia or cognitive decline warning currently appears on Pfizer’s gabapentin label. This omission is at the center of the gabapentin lawsuit program in Philadelphia. Plaintiffs argue that Pfizer possessed or should have possessed sufficient data to prompt a label update, and that its failure to do so left millions of patients and their physicians unable to make fully informed treatment decisions. You can review the FDA’s drug labeling standards to understand what pharmaceutical manufacturers are required to disclose about known risks.
Who Qualifies for the Gabapentin Lawsuit Program?
Not every individual prescribed gabapentin will qualify for the Philadelphia mass tort program or a related gabapentin lawsuit. Based on criteria emerging from early case filings and attorneys actively litigating these claims, the typical qualifying profile includes three core elements: (1) receipt of six or more gabapentin prescriptions, typically for an off-label condition such as chronic back pain, anxiety, or migraines rather than epilepsy or postherpetic neuralgia; (2) a subsequent diagnosis of early-onset dementia before age 65 or a documented diagnosis of mild cognitive impairment; and (3) no prior traumatic brain injury and no significant family history of Alzheimer’s disease that would complicate causation arguments.
Cases involving pregabalin (Lyrica), Pfizer’s successor gabapentinoid, are also being evaluated under the same program. Individuals who took Lyrica for fibromyalgia, diabetic neuropathy, or anxiety and later experienced neurocognitive decline may have claims that parallel those involving gabapentin. Because the damages in these cases — involving permanent cognitive injury and in some instances death — can be substantial, claimants evaluating potential compensation should consider that a brain injury calculator can help estimate the value of claims involving ongoing cognitive impairment resulting from defective pharmaceutical products. Eligibility determinations require individualized legal and medical review, and the status of litigation continues to evolve as the Philadelphia program moves through its early organizational phases.
It is also important to understand what this litigation currently is not: there is no nationwide federal MDL for gabapentin dementia claims as of October 2026, there has been no global settlement, and no settlement amounts have been announced. The Philadelphia state court program is the primary forum, and the litigation remains in its early stages. Justia’s pharmaceutical products liability resource provides helpful background on how drug injury litigation typically progresses through the court system.
Frequently Asked Questions About the Gabapentin Lawsuit
What is the gabapentin lawsuit in Philadelphia about?
The gabapentin lawsuit program established by the Philadelphia Court of Common Pleas on October 15, 2026 consolidates claims by individuals who allege that long-term use of gabapentin (Neurontin) or pregabalin (Lyrica) caused early-onset dementia or mild cognitive impairment. Plaintiffs allege that Pfizer failed to warn patients and physicians of these neurocognitive risks, engaged in off-label marketing fraud, and concealed relevant safety data. The program is a state-court mass tort consolidation — not a federal MDL — and no settlement has been reached.
What scientific evidence supports the gabapentin dementia claims?
Multiple peer-reviewed studies support the alleged link. A 2025 Case Western Reserve University study of 26,416 patients found that six or more gabapentin prescriptions were associated with a 29% higher 10-year dementia risk and an 85% higher MCI risk. A June 2026 meta-analysis in Drugs & Aging analyzing 325,245 participants found elevated odds of Alzheimer’s disease and related dementias among gabapentinoid users. A Frontiers in Pharmacology study found a 45% dementia risk increase, and National Alzheimer’s Coordinating Center data showed measurable cognitive decline within two years of starting gabapentin.
Who may qualify to file a gabapentin lawsuit?
Individuals who may qualify typically share three characteristics: they filled six or more gabapentin or pregabalin prescriptions, primarily for an off-label condition such as chronic pain, anxiety, or migraines; they received a diagnosis of early-onset dementia before age 65 or a mild cognitive impairment diagnosis; and they have no prior traumatic brain injury or significant family history of Alzheimer’s disease. Each case requires individual legal and medical evaluation, as qualifying criteria may evolve as the Philadelphia program develops.
Is there a federal MDL for gabapentin dementia cases?
No. As of October 2026, no federal multidistrict litigation program has been established for gabapentin dementia claims. The Philadelphia Court of Common Pleas mass tort program is the primary litigation hub. This means cases are being handled at the state court level in Pennsylvania, which is a common approach when litigation is in early stages or when state-court consolidation offers procedural advantages for plaintiffs.
Has Pfizer settled any gabapentin dementia lawsuits?
No settlement for gabapentin dementia or cognitive decline claims has been announced as of October 2026. The Philadelphia mass tort program was only formally established on October 15, 2026, and the litigation is in its early organizational phase. It is worth noting that Pfizer has previously settled gabapentin-related litigation on different grounds — including a $430 million criminal and civil settlement in 2004 for illegal off-label marketing, and additional settlements of $325 million and $190 million for marketing and antitrust violations — but none of those settlements addressed dementia or neurocognitive injury claims.
Legal disclaimer: The information on this page is provided for general informational purposes only and does not constitute legal advice; consult a licensed attorney in your jurisdiction for guidance specific to your situation.
Related reading: Physician Assistant Malpractice Settlement Amounts: 2026 Data, Verdicts & How Compensation Is Calculated
Related reading: Affidavit Of Merit In Medical Malpractice: State Rules, Federal Court Exceptions & What The 2026 Supreme Court Ruling Means For Your Case
Related reading: Portland $5.1M Parking Visibility Verdict 2026: Municipal Liability When Parked Cars Block Intersection Sightlines
Related reading: COVID-Era Immunity In Medical Malpractice: What 2026 State Court Rulings Mean For Patients Who Were Harmed During The Pandemic
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.